BCRX
+0.12 (1.12%)
10.88
03:50 PM
V: 3.45M
C: 10.88
L: 10.33
H: 10.95
O: 10.84
loading chart ...
  • 1d
  • 5d
  • 1m
  • 3m
  • 6m
  • ytd
  • 1y
  • 2y
  • 5y
  • max

General
Line Type
Scale Type
Ordinate Axis
Background
Area Color
Area Gradient
Up / Down Area
Show Volume
Volume SMA
Comparison
  • ZIVO Bioscience (OTCMKTS:ZIVO) & BioCryst Pharmaceuticals (NASDAQ:BCRX) Critical Comparison
    •

  • BioCryst Stock: A Prudent Diversification (NASDAQ:BCRX)
    •

  • Stocks Rally as Major Indexes Look to End Losing Streaks
    •

  • Here's What BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shareholder Ownership Structure Looks Like
    •

  • Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?
    •

  • Why BioCryst Pharmaceuticals Topped the Market Today
    •

  • 7 Cheap Biotech Stocks to Buy Now
    •

  • BioCryst to Present at Upcoming Investor Conferences
    •

  • Why BioCryst Stock Lost Nearly 4% of Its Value Today
    •

  • Why BioCryst Stock Shot Nearly 5% Higher Today
    •

  • BioCryst to Report First Quarter 2022 Financial Results on May 5
    •

  • Why BioCryst Pharmaceuticals Stock Sank Today
    •

  • Why BioChryst Pharmaceuticals' Stock Jumped 14.7% This Week
    •

  • Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?
    •

  • BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down
    •

  • Why BioCryst Pharmaceuticals Stock Is Falling
    •

  • BioCryst to Present at Upcoming Investor Conference
    •

  • Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder
    •

  • Why BioCryst Pharmaceuticals Stock Is Plunging Today
    •

  • Why BioCryst Pharmaceuticals Stock Slid Today
    •

  • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2021 Results - Earnings Call Transcript
    •

  • BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates
    •

  • Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts?
    •

  • Updated Guidance And Royalty Pharma Financing Demolish Short Thesis For BioCryst Pharmaceuticals
    •

  • BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting
    •

  • Why BioCryst Pharmaceuticals Stock Is Skyrocketing This Week
    •

  • BioCryst Pharmaceuticals Stock (BCRX): Why The Price Surged Today
    •

  • Why BioCryst Pharmaceuticals Stock Is Jumping on Monday
    •

  • BioCryst Provides Tremendous Option Value
    •

  • BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
    •

  • BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930
    •

  • BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo
    •

  • 7 Top Growth Stocks to Buy as We Step Into November
    •

  • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2021 Results - Earnings Call Transcript
    •

  • Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today
    •

  • BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
    •

  • BioCryst to Report Third Quarter 2021 Financial Results on November 3
    •

  • 7 Best Growth Stocks to Buy and Hold for the Next 10 Years
    •

  • 2 Super-Charged Growth Stocks to Buy Now
    •

  • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    •

  • 3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better
    •

  • NICE Recommends BioCryst's Hereditary Angioedema Med
    •

  • NICE Recommends BioCryst's ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK
    •

  • What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
    •

  • BioCryst to Present at Upcoming Investor Conferences
    •

  • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    •

  • US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med
    •

  • U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile
    •

  • BioCryst Appoints Dr. Steven Galson to Board of Directors
    •

  • BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic
    •

  • 2 Soaring Biotech Stocks With More Fuel in the Tank
    •

  • BioCryst Stock Jumps After Pulling Out $200M Equity Raise
    •

  • BioCryst Withdraws Public Offering
    •

  • Why BioCryst Pharmaceuticals Rose 8% on Thursday
    •

  • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2021 Results - Earnings Call Transcript
    •

  • BioCryst Pharma Stock Heads Higher Thursday: Here's Why
    •

  • Tuesday Afternoon Analyst Upgrades and Downgrades: Exxon Mobil, First Solar, Tesla and More
    •

  • 3 Biotech Stocks That Could Rocket Higher
    •

  • BioCryst to Report Second Quarter 2021 Financial Results on August 5
    •

  • BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
    •

  • BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder
    •

  • BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks
    •

  • BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline
    •

  • ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
    •

  • Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
    •

  • Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher?
    •

  • BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health
    •

  • 7 A-Rated Biotech Stocks to Buy Now
    •

  • BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside
    •

  • Forget AMC, GameStop: Analyst Names 2 New Reddit Stocks Traders Should Watch
    •

  • Is BioCryst a Good Stock to Buy Now?
    •

  • Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
    •

  • Why BioCryst Pharmaceuticals Stock Is Jumping Today
    •

  • BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
    •

  • Strength Seen in BioCryst (BCRX): Can Its 21% Jump Turn into More Strength?
    •

  • BioCryst: Solid Delivery And Follow Through
    •

  • BCRX Stock: 24.35% Increase (From $10.68 To $13.28) Intraday Explanation
    •

  • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q1 2021 Results - Earnings Call Transcript
    •

  • BioCryst Shares Trading Higher As Q1 Sales Beat Was Supported By Orladeyo Revenues
    •

  • Why BioCryst Pharmaceuticals Stock Is Soaring Today
    •

  • BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
    •

  • BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema
    •

  • BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
    •

  • BCRX Stock Price: $15 Target By Piper Sandler
    •

  • BioCryst Technical Levels To Watch
    •

  • FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings
    •

  • BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer
    •

  • BioCryst, Editas, Groupon, Sunrun, Twitter and More of Monday Afternoon's Analyst Calls
    •

  • BioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema
    •

  • BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
    •

  • Why BioCryst Pharmaceuticals Stock Is Falling Today
    •

  • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2020 Results - Earnings Call Transcript
    •

  • BioCryst Short-Sellers Lose Control
    •

  • BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25
    •

  • BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting
    •

  • Is it the right moment for investing in BioCryst Pharmaceuticals shares?
    •

  • BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older
    •

  • BioCryst Shares Slide As Reddit-Induced Rally Peters Out
    •

  • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    •

  • Implied Volatility Surging for BioCryst (BCRX) Stock Options
    •

News ...
ZIVO Bioscience (OTCMKTS:ZIVO) & BioCryst Pharmaceuticals (NASDAQ:BCRX) Critical Comparison defenseworld.net •
BioCryst Stock: A Prudent Diversification (NASDAQ:BCRX) seekingalpha.com •
Stocks Rally as Major Indexes Look to End Losing Streaks schaeffersresearch.com •
Here's What BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shareholder Ownership Structure Looks Like uk.sports.yahoo.com •
Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength? zacks.com •
Why BioCryst Pharmaceuticals Topped the Market Today fool.com •
Profile ...
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning ...
Date For Estimate Reported Surprise surprise %
2022-08-04 2022-06 -0.36 N/A N/A N/A
2022-05-05 2022-03 -0.39 -0.4 -0.01 -2.56%
2022-02-23 2021-12 -0.31 -0.4 -0.09 -29.03%
2021-11-03 2021-09 -0.3 -0.33 -0.03 -10.00%
2021-08-05 2021-06 -0.22 -0.24 -0.02 -9.09%
2021-05-06 2021-03 -0.26 -0.36 -0.1 -38.46%
Upgrade / Downgrade ...
Date Firm Action From To
2022-04-18 Barclays Downgrade Overweight Equal-Weight
2022-04-12 RBC Capital Upgrade Sector Perform
2022-04-11 B of A Securities Downgrade Buy Neutral
2022-04-11 Oppenheimer Upgrade Outperform
2021-12-10 Oppenheimer Upgrade Outperform
2021-11-04 RBC Capital Upgrade Sector Perform
Insider Holder ...
Date Name Relation Quantity Description
2022-06-06 ABERCROMBIE GEORGE B Director 12.87K Stock Award(Grant)
2022-06-06 ASELAGE STEPHEN J Director 46.59K Stock Award(Grant)
2022-06-06 GALSON STEVEN K Director 12.87K Stock Award(Grant)
2022-06-06 HEGGIE THERESA Director 30.23K Stock Award(Grant)
2022-06-06 HUTSON NANCY J Director 77.94K Stock Award(Grant)
2022-06-06 INGRAM ROBERT ALEXANDER Director 95.00K Stock Award(Grant)
Institution Ownership ...
Report Date Organization Position Value Percentage
2022-03-30 Blackrock Inc. 14.10M 229.30M 7.60%
2022-03-30 Vanguard Group, Inc. (The) 13.21M 214.75M 7.12%
2022-03-30 Baker Brothers Advisors, LLC 12.71M 206.68M 6.85%
2022-03-30 FMR, LLC 8.41M 136.82M 4.53%
2022-03-30 State Street Corporation 7.46M 121.34M 4.02%
2022-03-30 Pictet Asset Management SA 5.11M 83.04M 2.75%
Fund Ownership ...
Report Date Organization Position Value Percentage
2022-03-30 Vanguard Total Stock Market Index Fund 5.26M 85.54M 2.83%
2022-04-29 Fidelity Select Portfolios - Biotechnology 4.19M 38.95M 2.26%
2022-04-29 iShares Russell 2000 ETF 3.96M 36.81M 2.14%
2022-04-29 SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF 3.71M 34.50M 2.00%
2022-03-30 Vanguard Extended Market Index Fund 2.39M 38.83M 1.29%
2022-03-30 Vanguard Small-Cap Index Fund 2.25M 36.59M 1.21%
Dividend ...
Dividend Date
0 2014-06-11
0 2014-06-05
0 2014-05-20
0 2014-05-16
0 2014-04-02
Loading More Posts
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • oriley.services
    oriley.services last edited by

    $BCRX Great we’ve got Imacouk sharing knowledge this morning it’s gona be a good day?

    1 Reply Last reply Reply Quote 0
    • oriley.services
      oriley.services last edited by

      $BCRX Where is this guy mike smith getting subway sandwiches for $4.00 in Dallas there all $5.50.

      1 Reply Last reply Reply Quote 0
      • oriley.services
        oriley.services last edited by

        $BCRX Well since my account is going to hell in a hand basket and my family relies on me I’m going to go to my beach house for the week and think about it………now what was I thinking about? Heaven help us all.

        1 Reply Last reply Reply Quote 0
        • oriley.services
          oriley.services last edited by

          $BCRX $4.67 how wet it is!

          1 Reply Last reply Reply Quote 0
          • oriley.services
            oriley.services last edited by

            $BCRX Wow Mikey this thing is gona take off …run and tell your mommy

            1 Reply Last reply Reply Quote 0
            • oriley.services
              oriley.services last edited by

              $BCRX I needed a smile…thanks

              1 Reply Last reply Reply Quote 0
              • oriley.services
                oriley.services last edited by

                $BCRX

                Who’s it gonna bbbe

                1 Reply Last reply Reply Quote 0
                • oriley.services
                  oriley.services last edited by

                  $BCRX Let my people go you raskley rats

                  1 Reply Last reply Reply Quote 0
                  • oriley.services
                    oriley.services last edited by

                    $BCRX BINGO

                    1 Reply Last reply Reply Quote 0
                    • oriley.services
                      oriley.services last edited by

                      $BCRX Creatine levels are leveling out …good news

                      1 Reply Last reply Reply Quote 0
                      • oriley.services
                        oriley.services last edited by

                        ‘$BCRX I’m glad to see someone else is concerned about something not just the Sea Turd

                        1 Reply Last reply Reply Quote 0
                        • oriley.services
                          oriley.services last edited by

                          $BCRX @Harrington with all the trash you spout this is about as far as your going to get buddy

                          1 Reply Last reply Reply Quote 0
                          • oriley.services
                            oriley.services last edited by

                            $BCRX I think it’s time

                            1 Reply Last reply Reply Quote 0
                            • oriley.services
                              oriley.services last edited by

                              $BCRX BASTARDS BASTARDS BASTARDS……….

                              1 Reply Last reply Reply Quote 0
                              • oriley.services
                                oriley.services last edited by

                                $BCRX So much for that 1k share add at “this is going to be the bottom” price of 9.97.

                                1 Reply Last reply Reply Quote 0
                                • oriley.services
                                  oriley.services last edited by

                                  $BCRX You ever felt like you’ve been stabbed in the back…just wondering?

                                  1 Reply Last reply Reply Quote 0
                                  • oriley.services
                                    oriley.services last edited by

                                    $BCRX @Spencer I did the same thing, a lot of hopes and dreams dashed.

                                    1 Reply Last reply Reply Quote 0
                                    • oriley.services
                                      oriley.services last edited by

                                      $BCRX May help control the bleeding…sorry

                                      1 Reply Last reply Reply Quote 0
                                      • oriley.services
                                        oriley.services last edited by

                                        $BCRX @experiment 626 You might have Menorrhagia you might try Neproxen it may help go try the bleeding

                                        1 Reply Last reply Reply Quote 0
                                        • 1
                                        • 2
                                        • 3
                                        • 4
                                        • 5
                                        • 18
                                        • 19
                                        • 1 / 19
                                        • First post
                                          Last post